(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine 4-methylbenzenesulfonate
- Createtime： 2026-04-14
- Updatetime： 2026-04-15
Product Details
| useage |
Industrial use
|
| deliveryInfo |
|
| appearance |
White to off-white crystalline powder
|
| Storage |
Inert atmosphere, 2–8 °C, sealed and dry
|
| aliasen |
|
| supplyCapacity |
50000Metric Ton/Month
|
| harbor |
Qingdao,China
|
| minorder |
1KG
|
- Appearance: White to off-white crystalline powder
- Purity (HPLC): ≥98.0%
- Enantiomeric Purity: ≥99.0%
- Moisture: ≤0.2%
- Residue on Ignition: ≤0.1%
- Heavy Metals: ≤10 ppm
- Related Substances: ≤0.5%
Applications
- Pharmaceutical Intermediate: Key intermediate for synthesizing Aprepitant (NK1 receptor antagonist), used to prevent chemotherapy-induced nausea and vomiting (CINV)。
- Fine Chemicals: Used in the synthesis of complex morpholine derivatives and fluorinated aromatic compounds.
- Research & Development: As a reference standard and impurity marker in pharmaceutical analysis.
Safety Information
GHS Hazard: May cause skin irritation (H315), eye irritation (H319), and respiratory irritation (H335).
- Handling: Wear nitrile gloves, safety goggles, and dust mask; operate in a fume hood.
- Storage: Keep sealed under inert gas (nitrogen/argon) at 2–8 °C; avoid moisture, heat, and strong oxidants.
- Disposal: Dispose of as hazardous waste in accordance with local regulations.
